Atlas Trials

Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia

Clinical trial NCT03896945 · TERMINATED

Trial details

NCT number
NCT03896945
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Status
TERMINATED
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Schizophrenia
Start date
2019-02-15
Primary completion
2023-05-23
Enrollment
136

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.